Trials / No Longer Available
No Longer AvailableNCT00931086
Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99
An Expanded Access Trial of Belimumab Antibody (Monoclonal Anti-BLyS Antibody) in Patients With Rheumatoid Arthritis (RA) Who Were Previously Treated Under HGS Protocol LBRA99
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Human Genome Sciences Inc., a GSK Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An expanded access trial of belimumab for named patients who participated in LBRA99.
Detailed description
An expanded access trial of belimumab for named patients with Rheumatoid Arthritis (RA) who have experienced continued benefit under HGS Protocol LBRA99.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | belimumab | IV 10mg/kg q28days |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2009-07-02
- Last updated
- 2012-10-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00931086. Inclusion in this directory is not an endorsement.